UK Terminates COVID-19 Vaccine Deal, But Valneva Can Bounce Back
Two Other Vaccines Show Promise
Executive Summary
The UK’s decision has hit Valneva’s share price hard, but its vaccine candidates in Chikungunya and Lyme’s disease should help the firm bounce back.
You may also be interested in...
Valneva’s COVID-19 Vaccine Approved In UK While Talks Continue Over Scrapped Supply Deal
The MHRA has become the first regulatory agency worldwide to grant a marketing authorization for the inactivated whole virus COVID-19 vaccine, VLA2001.
Clive Dix: Industry Veteran, Vaccines Expert And Biotech Advocate
With more than 30 years’ experience in pharma and biotech, Clive Dix has seen the industry evolve and take on many challenges. He spoke to Scrip about his career journey, the future of biotech and his expectations for 2022 – another year under the cloud of COVID-19.
Clive Dix: Industry Veteran, Vaccines Expert And Biotech Advocate
Clive Dix was awarded Scrip’s Lifetime Achievement honor jointly with his long-term colleague and friend Dame Kate Bingham in December 2021. With more than 30 years’ experience in pharma and biotech, Dix has seen the industry evolve and take on many challenges. He spoke to In Vivo about his career journey, the future of biotech and his expectations for 2022 – another year under the cloud of COVID-19.